Skip to content

US · OGI · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Organigram Global Inc. (OGI) intrinsic value and stock valuation

$0.58as of 2026-11-21 · Mkt cap 139.37M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Organigram Global Inc. DCF and intrinsic value

InvestorsCraft values OGI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OGI’s statements →

Organigram Global Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Toronto, ON M5H 1J8 organigram.ca

How the business is doing

Fiscal 2012–2025, USD

Revenue
$186.1M+16.5% 5y CAGRd
20122025
Net income
-$-17.78M
20122025
Free cash flow
-$-16.52M
20122025
Total equity
$349.1M+3.1% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$186.1M$159.8M$149.2M$145.8M$79.2M
Operating income-$-63.41M-$-35.67M-$-242.74M-$-43.15M-$-91.82M
Net income-$-17.78M-$-45.44M-$-229.48M-$-14.28M-$-130.7M
EPSd-$-139.27K-$-476.86K-$-2.82M-$-167.41K-$-2.04M
Operating cash flow-$-4.3M$3.87M-$-35.8M-$-36.21M-$-28.59M
Capital expenditure-$-12.22M-$-5.34M-$-26.9M-$-48.78M-$-12.33M
Free cash flow-$-16.52M-$-1.47M-$-62.7M-$-84.99M-$-40.92M
Total assets$562.2M$407.9M$298.5M$577.1M$554M
Total debt$8.75M$4.46M$3.71M$3.36M$5.95M
Net debt-$-19.45M-$-102.29M-$-30.16M-$-65.16M-$-49.42M
Total equity$349.1M$306M$271.6M$508.1M$479.8M
Cash and short-term investments$29M$107.6M$33.9M$98.9M$183.8M
Income statement
20252024202320222021
Revenue$186.1M$159.8M$149.2M$145.8M$79.2M
Cost of revenue$179.3M$112.3M$114.1M$114.2M$107.6M
Gross profit$6.83M$47.5M$35.1M$31.6M-$-28.4M
Research and development expenses$11M$11.2M$12.2M$5.96M$3.45M
Selling, general and administrative expenses$86.9M$68.1M$71.7M$59.2M$46.5M
Other expenses-$-27.59M$3.85M$194M$5.14M-$-5.53M
Operating expenses$70.2M$83.2M$271.5M$74.7M$63.4M
Cost and expenses$249.5M$195.5M$385.6M$189M$171M
Interest income$830K$0.00$3.69M$0.00$0.00
Interest expense$0.00$0.00$280K$430K$2.96M
Depreciation and amortization$12.9M$12.1M$23.4M$24.9M$31M
Ebitda-$-14.76M-$-23.59M-$-25.36M$11M-$-96.71M
Operating income-$-63.41M-$-35.67M-$-242.74M-$-43.15M-$-91.82M
Total other income/expenses, net$35.7M-$-9.77M-$-184.21M$28.8M-$-38.88M
Income before tax-$-27.66M-$-45.44M-$-233M-$-14.37M-$-130.7M
Income tax expense-$-9.89M$0.00-$-3.52M-$-90K$0.00
Net income-$-17.78M-$-45.44M-$-229.48M-$-14.28M-$-130.7M
Weighted average shares outstanding$127.7M$95.3M$81.3M$80M$64M
Weighted average diluted shares outstanding$127.7M$95.3M$81.3M$85.3M$64M
Balance sheet
20252024202320222021
Cash and short-term investments$29M$107.6M$33.9M$98.9M$183.8M
Net receivables$64.9M$37.2M$27.5M$46.4M$21M
Inventory$124M$82.5M$81M$68.3M$48.8M
Total current assets$284.9M$262.2M$156M$221.6M$260.6M
Property, plant and equipment, net$123M$96.2M$99.1M$259.8M$235.9M
Goodwill and intangible assets$101M$8.09M$10.6M$56.2M$17.1M
Long-term investments$49.6M$40.7M$13.7M$7.07M$6.11M
Total non-current assets$277.3M$145.6M$142.5M$355.5M$293.4M
Total assets$562.2M$407.9M$298.5M$577.1M$554M
Accounts payable$89.3M$47.1M$14.7M$40.9M$19M
Short-term debt$1M$1.09M$80K$1M$1.06M
Deferred revenue$0.00$0.00$0.00$2.44M$0.00
Total current liabilities$126.2M$53.3M$22.4M$55.3M$26.3M
Long-term debt$7.75M$3.37M$6.24M$2.36M$4.88M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$86.9M$48.6M$4.4M$13.8M$48M
Capital lease obligations$8.73M$4.37M$2.61M$3.12M$5.63M
Total liabilities$213.1M$101.9M$26.8M$69.1M$74.2M
Common stock$919.9M$852.9M$776.9M$769.7M$730.8M
Retained earnings-$-608.73M-$-583.97M-$-538.53M-$-289.93M-$-275.64M
Accumulated other comprehensive income (loss)$38M$37.1M$33.2M$28.3M$24.7M
Total equity$349.1M$306M$271.6M$508.1M$479.8M
Total investments$50.4M$41.6M$13.7M$37.5M$134.6M
Total debt$8.75M$4.46M$3.71M$3.36M$5.95M
Net debt-$-19.45M-$-102.29M-$-30.16M-$-65.16M-$-49.42M
Cash flow statement
20252024202320222021
Net income-$-24.76M-$-45.44M-$-229.48M-$-14.28M-$-130.7M
Depreciation and amortization$18M$12.1M$24.1M$24.9M$31M
Stock-based compensation$4.22M$7.18M$5.29M$5.13M$3.9M
Change in working capital-$-2.12M$15M$12.5M-$-22.88M$24.2M
Accounts receivable-$-15.29M-$-12.06M$12.5M-$-24.02M-$-6.01M
Inventory$0.00$0.00$0.00-$-12.22M$28.7M
Accounts payable$0.00$0.00$0.00$12.2M$2.06M
Net cash provided by operating activities-$-4.3M$3.87M-$-35.8M-$-36.21M-$-28.59M
Investments in property, plant and equipment-$-17.02M-$-4.73M-$-26.9M-$-48.78M-$-12.33M
Acquisitions, net-$-65.62M$0.00$0.00-$-11.06M-$-2.54M
Net cash used for investing activities-$-59.35M-$-38.77M$4.56M$44M-$-115.11M
Common stock issued$29.6M$108.6M$20K$6.34M$284.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$28.2M$107.8M-$-750K$5.33M$174.5M
Net change in cash-$-37.98M$72.9M-$-68.52M$13.2M$30.8M
Cash at end of period$60M$106.8M$33.9M$68.5M$55.4M
Operating cash flow-$-4.3M$3.87M-$-35.8M-$-36.21M-$-28.59M
Capital expenditure-$-12.22M-$-5.34M-$-26.9M-$-48.78M-$-12.33M
Free cash flow-$-16.52M-$-1.47M-$-62.7M-$-84.99M-$-40.92M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Organigram Global Inc.

        Organigram Global Inc., primarily operating through its subsidiary Organigram Holdings Inc., is a Canadian enterprise specializing in the cultivation, production, and distribution of cannabis and related products. The company serves the medical cannabis market by offering products such as cannabis flowers, oils, and vaporizing devices to both civilian patients and military veterans. For adult recreational consumers, Organigram provides a diverse range of cannabis products, including edibles and concentrates, under popular brands like Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour. Additionally, the company acts as a wholesale supplier, distributing cannabis plant cuttings, dried flowers, proprietary blends, pre-rolled products, and various cannabis derivatives to retailers and other wholesalers within the adult-use recreational sector. Customers can purchase Organigram's offerings through its online platform or via telephone orders. Established in 2013, the company's corporate headquarters are located in Moncton, Canada.

        CEO
        James H. Yamanaka
        Employees
        1.12K
        Beta
        1.85

        Explore

        Frequently asked questions

        What is the intrinsic value of Organigram Global Inc. (OGI)?

        InvestorsCraft does not currently publish an intrinsic value for OGI. How the IC value is calculated.

        Is OGI undervalued?

        InvestorsCraft does not publish an undervaluation signal for OGI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.